Register an account to search through 14,000+ stocks! 

Ad

IMPL – Impel Neuropharma Inc

Ad

✔ COMPLIANT

★★☆

Biotechnology & Medical Research | USA

Business: PASS

Impel Neuropharma Inc has cleared the Business screen. Its business activity is compliant with the Shariah standard. If you find this result mistaken or questionable, let us know in the comments.

Financials: PASS

The financials pass two standards and fail in one.

FTSE

Debt/A69.75%
Cash/A58.84%
(AR+C)/A58.84%

AAOIFI

Debt/MC4.34%
Cash/MC%

DJIM

Debt/24MC3.41%
Cash/24MC2.88%
AR/24MC%

Total Analysts: 3

Recommendation Rating

1.3

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 45.7

Low: 3

High: 55

Market cap193991689
Assets12059000
Dividends per Share0
Revenue Growth

Impel NeuroPharma, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system (CNS). The Company offers Precision Olfactory Delivery (POD), which is a upper nasal delivery technology with well-established therapeutics or other therapeutics where vascular absorption is preferred to drive therapeutic benefit, improve patient outcomes, reduce drug development risk and expand the commercial opportunity within its target diseases. The Company’s product candidates TRUDHESATM (INP104) are developed for providing acute treatment of migraine and INP105 for the acute treatment of agitation and aggression in patients with Autism Spectrum Disorder (ASD). Its pipeline of proprietary product candidates also includes INP107 for the treatment of OFF episodes in Parkinson’s Disease.

✘ FTSE✔ AAOIFI✔ DJIM

✔ COMPLIANT

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.

Ad

Responses